NCT02277691View on ClinicalTrials.gov

A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

341

Participants

Timeline

Start Date

November 7, 2014

Primary Completion Date

April 25, 2016

Study Completion Date

April 25, 2016

Conditions
Essential Hypertension
Interventions
DRUG

TAK-536TCH tablet

TAK-536TCH tablets

DRUG

TAK-536CCB tablet

TAK-536CCB tablets

DRUG

HCTZ 12.5 mg tablet

HCTZ tablets

Trial Locations (38)

Unknown

Nagoya

Chiba

Itojima-shi

Kouriyama-shi

Sapporo

Amagasaki-shi

Tsukuba

Morioka

Sakaide-shi

Takamatsu

Kawasaki-shi

Kyoto

Uji-shi

Sendai

Hirakata-shi

Osaka

Takatsuki-shi

Saitama-shi

Tokorozawa-shi

Yaizu-shi

Chiyoda-ku

Choufu-shi

Kodaira-shi

Koutou-ku

Setagaya-ku

Shinagawa-ku

Shinjuku-ku

Choufu-shi

Kawasaki-shi

Koutou-ku

Morioka

Sakaide-shi

Setagaya-ku

Shinagawa-ku

Shinjuku-ku

Tsukuba

Uji-shi

Yaizu-shi

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT02277691 - A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension | Biotech Hunter | Biotech Hunter